Yahoo · Oct 22, 2026
AbCellera to Present at Upcoming Investor Conferences in November 2026
VANCOUVER, British Columbia, October 22, 2026--AbCellera to Present at Upcoming Investor Conferences in November 2026
AB
NASDAQ · ABCL
AbCellera Biologics Inc.
Healthcare · Biotechnology
$12.27
Down-$0.81 (-6.19%)
Updated Nov 2, 2026, 3:05 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.08B
- P/E ratio
- -7.37
- Dividend yield
- 0.00%
- 52-week range
- $3.22 – $15.02
- Volume
- 3.88M
- Avg. volume
- 4.11M
Price performance · ABCL
ABCL price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ABCL closed at $12.27 after 20 trading sessions, down 10.96% for the selected period.
- Last close
- $12.27
- Period change
- -10.96%
- Period low
- $11.37
- Period high
- $13.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $12.65 | $12.91 | $11.75 | $12.27 | 3.88M |
| Oct 29, 2026 | $13.41 | $13.86 | $13.02 | $13.08 | 2.62M |
| Oct 28, 2026 | $12.67 | $13.65 | $12.6537 | $13.64 | 3.06M |
| Oct 27, 2026 | $11.98 | $12.89 | $11.85 | $12.83 | 3.46M |
| Oct 26, 2026 | $12.02 | $12.415 | $11.78 | $12.08 | 3.04M |
| Oct 23, 2026 | $11.45 | $11.895 | $11.08 | $11.82 | 3.03M |
| Oct 22, 2026 | $11.985 | $12.23 | $11.205 | $11.37 | 4.28M |
| Oct 21, 2026 | $11.78 | $12.365 | $11.59 | $12.24 | 3.22M |
| Oct 20, 2026 | $11.65 | $11.945 | $11.41 | $11.71 | 4.26M |
| Oct 19, 2026 | $12.045 | $12.28 | $11.75 | $11.93 | 3.14M |
| Oct 16, 2026 | $12.68 | $12.68 | $11.72 | $11.80 | 4.11M |
| Oct 15, 2026 | $11.94 | $12.86 | $11.6915 | $12.68 | 5.76M |
| Oct 14, 2026 | $12.37 | $12.84 | $12.26 | $12.37 | 3.06M |
| Oct 13, 2026 | $12.53 | $12.72 | $12.20 | $12.61 | 3.25M |
| Oct 12, 2026 | $12.71 | $13.055 | $12.43 | $12.635 | 5.76M |
| Oct 9, 2026 | $12.03 | $12.79 | $11.93 | $12.545 | 4.69M |
| Oct 8, 2026 | $12.54 | $12.6299 | $11.89 | $12.02 | 8.52M |
| Oct 7, 2026 | $12.85 | $13.4499 | $12.56 | $12.83 | 5M |
| Oct 6, 2026 | $14.00 | $14.53 | $12.933 | $13.15 | 9.79M |
| Oct 5, 2026 | $13.72 | $13.88 | $13.21 | $13.78 | 4.08M |
Latest ABCL news
The latest Smart Investors Daily articles mentioning ABCL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ABCL research
Overview
Company profile and research snapshot.
Company profile
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.17
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | UBS | Buy | — |
| Sep 29, 2026 | JP Morgan | Overweight | — |
| Sep 24, 2026 | Goldman Sachs | Neutral | — |
| Aug 11, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Stifel | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 12, 2026
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of +944.64% and +383.11%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?
Benzinga · Oct 12, 2026
UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18
UBS analyst Alice Nettleton initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $18.
Yahoo · Oct 9, 2026
AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws Focus
AbCellera Biologics (ABCL) drew fresh attention after disclosing it will present new Phase 1/2 data on its investigational antibody ABCL635 at The Menopause Society’s 2026 Annual Meeting. That clinical spotlight arrives after a sharp run, with AbCellera Biologics posting a 90 day share price return of 84.49% and a year to date share price gain of 265.74%. The 1 year total shareholder return of 126.85% points to strong recent momentum despite earlier long term volatility. Scan other health and...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
